Alkermes (ALKS) Other financing activities (2010 - 2026)
Alkermes' (ALKS) quarterly Other financing activities came in at $26.3 million in Q2 2026, up 1162.22% year-over-year from $2.1 million in Q2 2025, and up 67.32% quarter-over-quarter from $15.7 million in Q1 2026.
Analysis
Alkermes (ALKS) Other financing activities (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Other financing activities for 17 consecutive years, with $26.3 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other financing activities rose 1162.22% year-over-year to $26.3 million in Q2 2026; TTM through Jun 2026 was $53.8 million, a 18.65% increase from a year earlier, with the FY2025 full-year figure at $43.4 million, up 57.45% from the prior year.
- Other financing activities was $26.3 million for Q2 2026 at Alkermes, up from $15.7 million in the prior quarter.
- Over five years, Other financing activities peaked at $29.5 million in Q1 2025 and troughed at $622000.0 in Q3 2025.
- A 5-year average of $8.3 million and a median of $4.3 million in 2023 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities plunged 88.73% in 2025 and soared 1162.22% in 2026, its largest moves.
- Over 5 years, Other financing activities stood at $780000.0 in 2022, then surged by 111.15% to $1.6 million in 2023, then jumped by 398.97% to $8.2 million in 2024, then surged by 36.02% to $11.2 million in 2025, then jumped by 135.21% to $26.3 million in 2026.
- The last three Other financing activities figures came in at $26.3 million (Q2 2026), $15.7 million (Q1 2026), and $11.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.93 Bn | 625.17 Bn | 17.26 Bn |
| 2 | AbbVie | 443.06 Bn | 436.49 Bn | 12.70 Bn |
| 3 | Merck | 365.76 Bn | 358.62 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.47 Bn | 258.78 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.36 Bn | 44.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.97 Bn | 43.97 Bn | - |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.52 Bn | 18.86 Bn | 683.80 Mn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.29 Mn |
| Mar 31, 2026 | 15.71 Mn |
| Dec 31, 2025 | 11.18 Mn |
| Sep 30, 2025 | 622,000.00 |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Dec 31, 2024 | 8.22 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 11.23 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Sep 30, 2023 | 3.11 Mn |
| Jun 30, 2023 | 9.13 Mn |
| Mar 31, 2023 | 2.87 Mn |
| Dec 31, 2022 | 780,000.00 |
| Sep 30, 2022 | 858,000.00 |
| Jun 30, 2022 | 16.20 Mn |
| Mar 31, 2022 | 1.80 Mn |
| Dec 31, 2021 | 509,000.00 |
| Sep 30, 2021 | 4.31 Mn |